A Strain Change Study for SARS-CoV-2 rS Vaccines

Summary

The present study aims to investigate the safety and immunogenicity of the Novavax JN.1 subvariant vaccine SARS-CoV-2 rS adjuvanted with Matrix-M (NVX CoV2705) in previously vaccinated adults. A descriptive comparison will be made with participants who received the prior authorized vaccine NVX-CoV2601 in an earlier study (2019nCoV-313).

Timeline

Start

2024-10-14

Primary completion

2024-10-15

Completion

2025-04-17

Publications

• Alves K, Kouassi A, Nelson J, Plested JS, Kalkeri R, Zhu M, Cloney-Clark S, Cai Z, Ahmed A, McKnight I, Mallory RM, Noriega F. Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trial. Vaccine. 2026 Feb 15;73:128164. doi: 10.1016/j.vaccine.2025.128164. Epub 2025 Dec 26.

Drugs

Indications